{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:14:17Z","timestamp":1772831657779,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bone.2019.03.019","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T03:26:02Z","timestamp":1553225162000},"page":"191-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-232X","authenticated-orcid":false,"given":"A.","family":"Fassio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Benini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vantaggiato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.G.","family":"Saag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lippolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Orsolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.03.019_bb0005","doi-asserted-by":"crossref","unstructured":"E.V. McCloskey, H. Johansson, A. Oden, M. Austin, E. Siris, A. Wang, E.M. Lewiecki, R. Lorenc, C. Libanati, J.A. Kanis, Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 27 (2012) 1480\u20131486. doi:https:\/\/doi.org\/10.1002\/jbmr.1606.","DOI":"10.1002\/jbmr.1606"},{"key":"10.1016\/j.bone.2019.03.019_bb0010","doi-asserted-by":"crossref","unstructured":"H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwi\u0144ski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.-Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, Lancet Diabetes Endocrinol. 5 (2017) 513\u2013523. doi:https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9.","DOI":"10.1016\/S2213-8587(17)30138-9"},{"key":"10.1016\/j.bone.2019.03.019_bb0015","doi-asserted-by":"crossref","unstructured":"A.D. Anastasilakis, S.A. Polyzos, P. Makras, B. Aubry-Rozier, S. Kaouri, O. Lamy, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 32 (2017) 1291\u20131296. doi:https:\/\/doi.org\/10.1002\/jbmr.3110.","DOI":"10.1002\/jbmr.3110"},{"key":"10.1016\/j.bone.2019.03.019_bb0020","doi-asserted-by":"crossref","unstructured":"S.R. Cummings, S. Ferrari, R. Eastell, N. Gilchrist, J.-E.B. Jensen, M. McClung, C. Roux, O. T\u00f6rring, I. Valter, A.T. Wang, J.P. Brown, Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled freedom trial and its extension, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 33 (2018) 190\u2013198. doi:https:\/\/doi.org\/10.1002\/jbmr.3337.","DOI":"10.1002\/jbmr.3337"},{"key":"10.1016\/j.bone.2019.03.019_bb0025","doi-asserted-by":"crossref","unstructured":"H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, P.D. Miller, Y.-C. Yang, L. Grazette, J. San Martin, J.C. Gallagher, Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass, J. Clin. Endocrinol. Metab. 96 (2011) 972\u2013980. doi:https:\/\/doi.org\/10.1210\/jc.2010-1502.","DOI":"10.1210\/jc.2010-1502"},{"key":"10.1016\/j.bone.2019.03.019_bb0030","doi-asserted-by":"crossref","unstructured":"P.D. Miller, M.A. Bolognese, E.M. Lewiecki, M.R. McClung, B. Ding, M. Austin, Y. Liu, J. San Martin, Amg Bone Loss Study Group, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone. 43 (2008) 222\u2013229. doi:https:\/\/doi.org\/10.1016\/j.bone.2008.04.007.","DOI":"10.1016\/j.bone.2008.04.007"},{"key":"10.1016\/j.bone.2019.03.019_bb0035","doi-asserted-by":"crossref","unstructured":"A.W. Popp, N. Varathan, H. Buffat, C. Senn, R. Perrelet, K. Lippuner, Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis, Calcif. Tissue Int. 103 (2018) 50\u201354. doi:https:\/\/doi.org\/10.1007\/s00223-018-0394-4.","DOI":"10.1007\/s00223-018-0394-4"},{"key":"10.1016\/j.bone.2019.03.019_bb0040","doi-asserted-by":"crossref","unstructured":"M.B. Zanchetta, J. Boailchuk, F. Massari, F. Silveira, C. Bogado, J.R. Zanchetta, Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study, Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA. 29 (2018) 41\u201347. doi:https:\/\/doi.org\/10.1007\/s00198-017-4242-6.","DOI":"10.1007\/s00198-017-4242-6"},{"key":"10.1016\/j.bone.2019.03.019_bb0045","doi-asserted-by":"crossref","unstructured":"M. Rossini, D. Gatti, S. Adami, Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis, Calcif. Tissue Int. 93 (2013) 121\u2013132. doi:https:\/\/doi.org\/10.1007\/s00223-013-9749-z.","DOI":"10.1007\/s00223-013-9749-z"},{"key":"10.1016\/j.bone.2019.03.019_bb0050","doi-asserted-by":"crossref","unstructured":"R. Baron, J.M. Gertner, R. Lang, A. Vignery, Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda, Pediatr. Res. 17 (1983) 204\u2013207. doi:https:\/\/doi.org\/10.1203\/00006450-198303000-00007.","DOI":"10.1203\/00006450-198303000-00007"},{"key":"10.1016\/j.bone.2019.03.019_bb0055","doi-asserted-by":"crossref","unstructured":"E. Tsourdi, M.C. Zillikens, Certainties and uncertainties about denosumab discontinuation, Calcif. Tissue Int. 103 (2018) 1\u20134. doi:https:\/\/doi.org\/10.1007\/s00223-018-0436-y.","DOI":"10.1007\/s00223-018-0436-y"},{"key":"10.1016\/j.bone.2019.03.019_bb0060","doi-asserted-by":"crossref","unstructured":"D. Gatti, O. Viapiana, L. Idolazzi, E. Fracassi, C. Ionescu, C. Dartizio, S. Troplini, V. Kunnathully, S. Adami, M. Rossini, Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis, Bone. 67 (2014) 189\u2013192. doi:https:\/\/doi.org\/10.1016\/j.bone.2014.06.037.","DOI":"10.1016\/j.bone.2014.06.037"},{"key":"10.1016\/j.bone.2019.03.019_bb0065","doi-asserted-by":"crossref","unstructured":"D. Gatti, O. Viapiana, S. Adami, L. Idolazzi, E. Fracassi, M. Rossini, Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin, Bone. 50 (2012) 739\u2013742. doi:https:\/\/doi.org\/10.1016\/j.bone.2011.11.028.","DOI":"10.1016\/j.bone.2011.11.028"},{"key":"10.1016\/j.bone.2019.03.019_bb0070","doi-asserted-by":"crossref","unstructured":"D. Gatti, O. Viapiana, E. Fracassi, L. Idolazzi, C. Dartizio, M.R. Povino, S. Adami, M. Rossini, Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 27 (2012) 2259\u20132263. doi:https:\/\/doi.org\/10.1002\/jbmr.1681.","DOI":"10.1002\/jbmr.1681"},{"key":"10.1016\/j.bone.2019.03.019_bb0075","doi-asserted-by":"crossref","unstructured":"J. Colditz, S. Thiele, U. Baschant, C. Niehrs, L.F. Bonewald, L.C. Hofbauer, M. Rauner, Postnatal skeletal deletion of Dickkopf-1 increases bone formation and bone volume in male and female mice, despite increased sclerostin expression, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 33 (2018) 1698\u20131707. doi:https:\/\/doi.org\/10.1002\/jbmr.3463.","DOI":"10.1002\/jbmr.3463"},{"key":"10.1016\/j.bone.2019.03.019_bb0080","doi-asserted-by":"crossref","unstructured":"M.R. McClung, Cancel the denosumab holiday, Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA. 27 (2016) 1677\u20131682. doi:https:\/\/doi.org\/10.1007\/s00198-016-3553-3.","DOI":"10.1007\/s00198-016-3553-3"},{"key":"10.1016\/j.bone.2019.03.019_bb0085","doi-asserted-by":"crossref","unstructured":"P. Makras, S.A. Polyzos, A. Papatheodorou, P. Kokkoris, D. Chatzifotiadis, A.D. Anastasilakis, Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis, Clin. Endocrinol. (Oxf.). 79 (2013) 499\u2013503. doi:https:\/\/doi.org\/10.1111\/cen.12188.","DOI":"10.1111\/cen.12188"},{"key":"10.1016\/j.bone.2019.03.019_bb0090","doi-asserted-by":"crossref","unstructured":"P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, A.M. DePaoli, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 19 (2004) 1059\u20131066. doi:https:\/\/doi.org\/10.1359\/JBMR.040305.","DOI":"10.1359\/JBMR.040305"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821930095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821930095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:45:12Z","timestamp":1757612712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821930095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":18,"alternative-id":["S875632821930095X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.03.019","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}